CureDuchenne is dedicated to curing Duchenne muscular dystrophy (DMD) through innovative venture philanthropy that funds groundbreaking research, early diagnosis, and access to treatment, while providing education and support programs for those affected by the disease.
2003
20-0299958
$28.41 million
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
Providing support and education to families affected by Duchenne muscular dystrophy.
An overview of CureDuchenne's accomplishments and impact in the last year.
Join us at our various fundraising and community events.
Increased Life Expectancy
Since the inception of CureDuchenne, life expectancy for Duchenne has increased.
Clinical Trials Funded
18 projects funded by CureDuchenne have progressed to clinical trials.
Funds Raised
We’ve raised over $50 million for research, education, and care.
First FDA-Approved Drug
CureDuchenne contributed early funding for the first FDA-approved Duchenne drug.
Follow-on Funding Leveraged
Our model has leveraged over $3 billion in follow-on funding for future programs from investors and biotech companies.
December 5, 2024
Holiday shopping benefit to support CureDuchenne.
Learn MoreDecember 7, 2024
A session to discuss health and wellness for Duchenne families.
Learn MoreFebruary 16, 2025
Support Tim Revell's 20th Austin Marathon run.
Learn MoreFebruary 22, 2025
Join us for a night of philanthropy at the Segerstrom Shelby Event Center.
Learn MoreA program to support families and individuals affected by Duchenne through educational resources and care guidance.
Learn MoreOverall Score
66
60
/100
Program Expense Ratio
74.81%
10
/20
Program Revenue Growth
0.00%
2
/20
Leverage Ratio
0.01093
20
/20
Working Capital Ratio
3.12
16
/20
Fundraising Efficiency
1.36
12
/20
Fiscal Year:2022
Source:Source: Self-reported by organization
Category | Amount | Percentage |
---|---|---|
Contributions, Gifts, and Grants | 2.43M | 42.24% |
Program Services | 0 | 0.00% |
Investment Income | 362.7K | 6.31% |
Sales of Non-Inventory Assets | -215.1K | -3.74% |
Other Notable Sources | -32.93K | -0.57% |
Total Revenue | 5.751M | 100.00% |
Med Research
Orthopedic ResearchMed Research
Orthopedic ResearchMed Research
Orthopedic ResearchMed Research
Orthopedic ResearchMed Research
Orthopedic Research